Roche delays Spark merger again amid reviews in US and UKRoche’s $4.3 billion takeover of US gene therapy specialist Spark Therapeutics has been pushed back again because regulators Share XRoche delays Spark merger again amid reviews in US and UKhttps://pharmaphorum.com/news/roche-delays-spark-merger-again-amid-reviews-in-us-and-uk/
Roche to buy gene therapy firm Spark for $4.8 billionRoche is to buy gene therapy firm Spark Therapeutics for $4.8 billion, adding an already-approved treatment for inherited Share XRoche to buy gene therapy firm Spark for $4.8 billionhttps://pharmaphorum.com/news/roche-to-buy-spark-therapeutics/
Novartis/Spark’s sight gene therapy approved in EUSpark Therapeutics’ gene therapy for a rare inherited sight disorder, Luxturna has been approved in Europe, but there Share XNovartis/Spark’s sight gene therapy approved in EUhttps://pharmaphorum.com/news/novartis-sparks-sight-gene-therapy-approved-in-eu/
